OP
CYTK icon

ORG Partners’s Cytokinetics CYTK Stock Holding History

ORG Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.21K Buy
+19
New +$1.18K ﹤0.01% 1515

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ORG Partners's CYTK Position: Q4 2025 in Review

ORG Partners opened a new position in Cytokinetics (CYTK) in Q4 2025: 19 shares worth $1.21K. The stake represents ﹤0.01% of the portfolio and ranks #1515 among its holdings.

430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

  • ORG Partners held 19 shares of Cytokinetics worth $1.21K as of Q4 2025.
  • Cytokinetics was a new ORG Partners position in Q4 2025.
  • Cytokinetics made up ﹤0.01% of ORG Partners's portfolio in Q4 2025, its #1515 holding.
  • 430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.